ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0106

Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis
Abstract Number: 0663

iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Abstract Number: 0102

Iron Metabolism Dysregulation and Inflammation in Ankylosing Spondylitis: Role of SLC39A14 in Extracellular Matrix Remodeling
Abstract Number: 0612

Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Abstract Number: 1288

Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Abstract Number: 0500

Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Abstract Number: 0754

Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients
Abstract Number: 2483

Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
Abstract Number: 1673

Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study
Abstract Number: 2023

Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Abstract Number: 0785

It Takes a Community: Exploring the Importance of Community-Level Social Determinants of Health in Total Knee Arthroplasty Outcomes
Abstract Number: 1960

Item Response Theory to Develop an Ultrasound Composite Score for Knee Osteoarthritis Assessment
Abstract Number: 2355

Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
Abstract Number: 2375

Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
Abstract Number: 1239

JAK inhibition appears to alter clinical and neurobiological markers of nociplastic pain in rheumatoid arthritis: a 7T MRI Brain study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].